SILVER SPRING
Baxfendy cleared as first aldosterone synthase inhibitor for hypertension
- Sponsor
- AstraZeneca $AZN
- Drug
- Baxfendy · baxdrostat
- Indication
- hypertension
FDA approved AstraZeneca's Baxfendy (baxdrostat) as the first aldosterone synthase inhibitor for hypertension in combination with other antihypertensive medications.
What this means
Baxfendy is a blood pressure medication that works by blocking aldosterone production, a hormone that can cause stubborn high blood pressure. The FDA just approved Baxfendy for use alongside other blood pressure drugs in patients who need additional treatment. This gives doctors a new tool for hard-to-control hypertension by targeting a different pathway than existing medications.